Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
MicroRNAs are dysregulated in a setting of heart disease and have emerged as promising therapeutic targets. MicroRNA-34 family members (miR-34a, -34b, and -34c) are up-regulated in the heart in response to stress. In this study, we assessed whether inhibition of the miR-34 family using an s.c.-delivered seed-targeting 8-mer locked nucleic acid (LNA)-modified antimiR (LNA-antimiR-34) can provide therapeutic benefit in mice with preexisting pathological cardiac remodeling and dysfunction due to myocardial infarction (MI) or pressure overload via transverse aortic constriction (TAC). An additional cohort of mice subjected to MI was given LNA-antimiR-34a (15-mer) to inhibit miR-34a alone as a comparison for LNA-antimiR-34. LNA-antimiR-34 (8-mer) efficiently silenced all three miR-34 family members in both cardiac stress models and attenuated cardiac remodeling and atrial enlargement. In contrast, inhibition of miR-34a alone with LNA-antimiR-34a (15-mer) provided no benefit in the MI model. In mice subjected to pressure overload, LNA-antimiR-34 improved systolic function and attenuated lung congestion, associated with reduced cardiac fibrosis, increased angiogenesis, increased Akt activity, decreased atrial natriuretic peptide gene expression, and maintenance of sarcoplasmic reticulum Ca 2+ ATPase gene expression. Improved outcome in LNA-antimiR-34–treated MI and TAC mice was accompanied by up-regulation of several direct miR-34 targets, including vascular endothelial growth factors, vinculin, protein O -fucosyltranferase 1, Notch1, and semaphorin 4B. Our results provide evidence that silencing of the entire miR-34 family can protect the heart against pathological cardiac remodeling and improve function. Furthermore, these data underscore the utility of seed-targeting 8-mer LNA-antimiRs in the development of new therapeutic approaches for pharmacologic inhibition of disease-implicated miRNA seed families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“Modifications used to enhance the binding affinity of antimiRs to their cognate miRNAs and to facilitate cellular uptake for in vivo delivery include incorporation of 2′-O-methyl, 2′-O-methoxyethyl, locked nucleic acid (LNA), 3′ cholesterol conjugation (antagomiRs), and phosphorothioate backbone modification (3, 5, 7,…”
MethodLNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 2×
“Modifications used to enhance the binding affinity of antimiRs to their cognate miRNAs and to facilitate cellular uptake for in vivo delivery include incorporation of 2′-O-methyl, 2′-O-methoxyethyl, locked nucleic acid (LNA), 3′ cholesterol conjugation (antagomiRs), and phosphorothioate backbone modification (3, 5, 7,…”
BackgroundMethodSelf-citationPervasive roles of microRNAs in cardiovascular biology
Small, E. M., & Olson, E. N. (2011) · Nature · doi:10.1038/nature09783 · Cited by 1,180 · cited 3×
“Several previous studies have examined inhibition of individual miRNAs in the heart using chemically modified antisense oligonucleotides known as antimiRs (15-22 mer) (3, 4).”
BackgroundShiojima, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24682 · Cited by 939
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Self-citationMicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure
Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L. W., Doevendans, P. A., Mummery, C. L., Borlak, J., Haverich, A., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.687947 · Cited by 888
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
Self-citationSilencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
Self-citationThe Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N., & van Rooij, E. (2011) · Circulation · doi:10.1161/circulationaha.111.030932 · Cited by 603
Silent Information Regulator 1 Protects the Heart From Ischemia/Reperfusion
Hsu, C.-P., Zhai, P., Yamamoto, T., Maejima, Y., Matsushima, S., Hariharan, N., Shao, D., Takagi, H., Oka, S., & Sadoshima, J. (2010) · Circulation · doi:10.1161/circulationaha.110.958033 · Cited by 560
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Self-citationMcMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Kang, P. M., & Izumo, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934654100 · Cited by 534
Self-citationInhibition of miR-15 Protects Against Cardiac Ischemic Injury
Hullinger, T. G., Montgomery, R. L., Seto, A. G., Dickinson, B. A., Semus, H. M., Lynch, J. M., Dalby, C. M., Robinson, K., Stack, C., Latimer, P. A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.244442 · Cited by 501
McMurray, J. J. V. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0909392 · Cited by 455
Developing MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
miR-15 Family Regulates Postnatal Mitotic Arrest of Cardiomyocytes
Porrello, E. R., Johnson, B. A., Aurora, A. B., Simpson, E., Nam, Y.-J., Matkovich, S. J., Dorn, G. W., van Rooij, E., & Olson, E. N. (2011) · Circulation Research · doi:10.1161/circresaha.111.248880 · Cited by 444
McMullen, J. R., Shioi, T., Huang, W.-Y., Zhang, L., Tarnavski, O., Bisping, E., Schinke, M., Kong, S., Sherwood, M. C., Brown, J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310405200 · Cited by 404
Self-citationMcMullen, J. R., Amirahmadi, F., Woodcock, E. A., Schinke-Braun, M., Bouwman, R. D., Hewitt, K. A., Mollica, J. P., Zhang, L., Zhang, Y., Shioi, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606663104 · Cited by 299
Self-citationNalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
MicroRNA Dysregulation in Diabetic Ischemic Heart Failure Patients
Greco, S., Fasanaro, P., Castelvecchio, S., D’Alessandra, Y., Arcelli, D., Di Donato, M., Malavazos, A., Capogrossi, M. C., Menicanti, L., & Martelli, F. (2012) · Diabetes · doi:10.2337/db11-0952 · Cited by 234
miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2
Wei, J., Shi, Y., Zheng, L., Zhou, B., Inose, H., Wang, J., Guo, X. E., Grosschedl, R., & Karsenty, G. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201201057 · Cited by 218
Zemljic-Harpf, A. E., Miller, J. C., Henderson, S. A., Wright, A. T., Manso, A. M., Elsherif, L., Dalton, N. D., Thor, A. K., Perkins, G. A., McCulloch, A. D., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00728-07 · Cited by 208
Potent inhibition of microRNA in vivo without degradation
Davis, S., Propp, S., Freier, S. M., Jones, L. E., Serra, M. J., Kinberger, G., Bhat, B., Swayze, E. E., Bennett, C. F., & Esau, C. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn904 · Cited by 200
Lähteenvuo, J. E., Lähteenvuo, M. T., Kivelä, A., Rosenlew, C., Falkevall, A., Klar, J., Heikura, T., Rissanen, T. T., Vähäkangas, E., Korpisalo, P., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.816454 · Cited by 199
Intact p53-Dependent Responses in miR-34–Deficient Mice
Concepcion, C. P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J. A., Maughan, W. P., Ogrodowski, P., & Ventura, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002797 · Cited by 197 · cited 1×
“Recent reports demonstrate that inhibition of the miR-34 family does not promote tumorigenesis, supporting the potential for therapeutic suppression of this family as a treatment for heart failure (39).”
BackgroundPretorius, L., Du, X.-J., Woodcock, E. A., Kiriazis, H., Lin, R. C. Y., Marasco, S., Medcalf, R. L., Ming, Z., Head, G. A., Tan, J. W., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090126 · Cited by 187
Self-citationLin, R. C. Y., Weeks, K. L., Gao, X.-M., Williams, R. B. H., Bernardo, B. C., Kiriazis, H., Matthews, V. B., Woodcock, E. A., Bouwman, R. D., Mollica, J. P., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.201988 · Cited by 170
Self-citationWeeks, K. L., Gao, X., Du, X., Boey, E. J. H., Matsumoto, A., Bernardo, B. C., Kiriazis, H., Cemerlang, N., Tan, J. W., Tham, Y. K., et al. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.966622 · Cited by 159
Self-citationYe, W., Lv, Q., Wong, C.-K. A., Hu, S., Fu, C., Zhong, H., Cai, G., Li, G., Yang, B. B., & Zhang, Y. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001719 · Cited by 158
Silber, J., Skanderup, A. J., Ozawa, T., Harinath, G., Pedraza, A. M., Sander, C., Holland, E. C., & Huse, J. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033844 · Cited by 139
Cubbon, R. M., Gale, C. P., Kearney, L. C., Schechter, C. B., Brooksby, W. P., Nolan, J., Fox, K. A. A., Rajwani, A., Baig, W., Groves, D., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.959882 · Cited by 132
A MicroRNA Guide for Clinicians and Basic Scientists: Background and Experimental Techniques
Bernardo, B. C., Charchar, F. J., Lin, R. C. Y., & McMullen, J. R. (2011) · Heart Lung and Circulation · doi:10.1016/j.hlc.2011.11.002 · Cited by 115
Self-citationLi, Y., Hiroi, Y., & Liao, J. K. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2011.11.006 · Cited by 104
Pofut1 is required for the proper localization of the Notch receptor during mouse development
Okamura, Y., & Saga, Y. (2008) · Mechanisms of Development · doi:10.1016/j.mod.2008.04.007 · Cited by 78
The role of Bcl6 in mature cardiac myocytes
Yoshida, T. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00007-3 · Cited by 69
Identification of Semaphorin 4B as a Negative Regulator of Basophil-Mediated Immune Responses
Nakagawa, Y., Takamatsu, H., Okuno, T., Kang, S.-J., Nojima, S., Kimura, T., Kataoka, T., Ikawa, M., Toyofuku, T., Katayama, I., et al. (2011) · Journal of Immunology · doi:10.4049/jimmunol.1003485 · Cited by 46
Tamamori‐Adachi, M., Takagi, H., Hashimoto, K., Goto, K., Hidaka, T., Koshimizu, U., Yamada, K., Goto, I., Maejima, Y., Isobe, M., et al. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn183 · Cited by 42
Cited by
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
MicroRNA-34a regulates cardiac ageing and function.
Boon, R. A., Iekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., Kaluza, D., Tréguer, K., Carmona, G., Bonauer, A., et al. (2013) · Nature · doi:10.1038/nature11919 · Cited by 821
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Kalogeris, T., Baines, C. P., Krenz, M., & Korthuis, R. J. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c160006 · Cited by 718
Metadata
- Authors
- Bernardo, B. C., Gao, X.-M., Winbanks, C. E., Boey, E. J. H., Tham, Y. K., Kiriazis, H., Gregorevic, P., Obad, S., Kauppinen, S., Du, X.-J., Lin, R. C. Y., & McMullen, J. R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-10-09
- Volume
- 109
- Issue
- 43
- Pages
- 17615-17620
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2155794059
- Cited by
- 429
- References
- 39
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.